BioCentury
ARTICLE | Company News

Advanced Proteome, ImmunoBiochem to develop ADCs for TNBC

February 9, 2018 8:12 PM UTC

Advanced Proteome Therapeutics Corp. (TSX-V:APC; FSE:0E8) and ImmunoBiochem Corp. (Toronto, Ontario) will evaluate combining an undisclosed antibody from ImmunoBiochem with Advanced Proteome's site-selective conjugation technology to develop antibody-drug conjugates (ADCs) to treat triple-negative breast cancer (TNBC). ...